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Uma estratégia importante para a terapia do câncer é o planejamento de modulares que 
interferem na dinâmica dos microtúbulos através de sua ligação específica à subunidade β da 
tubulina. No presente trabalho, estudos de análise comparativa dos campos moleculares (CoMFA) 
foram realizados com uma série de análogos do discodermolídeo com ação antimitótica. Resultados 
significativos foram obtidos (CoMFA(i), q2 = 0,68, r2 = 0,94; CoMFA(ii), q2 = 0,63, r2 = 0,91), 
indicando a elevada consistência interna e externa dos modelos gerados empregando duas estratégias 
independentes de alinhamento estrutural. Os modelos foram validados externamente com um 
conjunto teste e os valores preditos apresentaram boa concordância com os resultados experimentais. 
Os modelos de QSAR e os mapas de contorno 3D forneceram importantes informações sobre as 
bases químicas e estruturais envolvidas no processo de reconhecimento molecular dessa família de 
análogos do discodermolídeo, sendo uma valiosa ferramenta no planejamento de novos moduladores 
específicos da β-tubulina com potente atividade antitumoral.
An important approach to cancer therapy is the design of small molecule modulators that 
interfere with microtubule dynamics through their specific binding to the β-subunit of tubulin. 
In the present work, comparative molecular field analysis (CoMFA) studies were conducted on a 
series of discodermolide analogs with antimitotic properties. Significant correlation coefficients 
were obtained (CoMFA(i), q2 = 0.68, r2 = 0.94; CoMFA(ii), q2 = 0.63, r2 = 0.91), indicating the 
good internal and external consistency of the models generated using two independent structural 
alignment strategies. The models were externally validated employing a test set, and the predicted 
values were in good agreement with the experimental results. The final QSAR models and the 3D 
contour maps provided important insights into the chemical and structural basis involved in the 
molecular recognition process of this family of discodermolide analogs, and should be useful for 
the design of new specific β-tubulin modulators with potent anticancer activity.
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Introduction
A rational approach to cancer therapy involves the design 
of small molecule ligands that interfere with microtubule 
dynamics through their specific binding to the β-subunit 
of tubulin, leading to mitotic arrest and cell death.1-6 Taxol 
(paclitaxel, Figure 1), a highly functionalized diterpenoid 
isolated from Taxus brevifolia (Pacific Yew tree), was the first 
compound recognized to interact specifically and reversibly 
with the β-subunit of the tubulin heterodimer, promoting 
microtubule stabilization and consequently, blocking cells 
in the mitotic phase of the cell cycle. The unique mechanism 
of action as a microtubule-stabilizing antimitotic agent 
(MSAA) is responsible by the extraordinary clinical success 
achieved by Taxol and related taxanes in the treatment 
of a variety of cancers. Although taxanes are the most 
prominent among the known MSAAs, their scarceness, 
poor pharmacokinetic properties, high systemic toxicity and 
resistance have led to the identification of novel compounds 
having similar mechanisms of action.6-10 These include 
non-taxane microtubule-stabilizing natural products, such 
as discodermolide, epothilone and dictyostatin (Figure 1). 
These promising anticancer agents competitively inhibit 
the binding of paclitaxel to tubulin polymers, indicating 
Structural and Chemical Basis for Anticancer Activity of a Series of β-Tubulin Ligands J. Braz. Chem. Soc.694
an overlapping binding site in the β-tubulin cavity, which 
can accommodate a variety of structurally diverse MSAAs 
in unique and independent ways.11-15
The marine polyketide discodermolide is one of the 
most potent MSAAs known. In addition to its potent 
antiproliferative and apoptosis-inducing activities, 
discodermolide is more water soluble than paclitaxel and 
retains substantial activity against taxane-resistant cell 
lines. These physicochemical and biological characteristics 
have qualified discodermolide as a lead compound for the 
development of new, more effective and safer anticancer 
agents.13-16
An important strategy in the design of new β-specific 
tubulin modulators is to identify key properties of the 
chemical structure related to their ability to induce a 
cytotoxic response as a consequence of modulation of 
microtubule functions through tubulin-binding. Structure 
and ligand-based drug design approaches have become 
fundamental components of modern drug discovery.17,18 
Quantitative structure-activity relationship (QSAR) 
methods have been successfully employed to assist the 
design of new small molecule drug candidates, ranging 
from enzyme inhibitors to receptor ligands.19-26 However, 
there is only a small number of QSAR studies found in 
the literature for taxoid-site tubulin modulators and, to 
the best of our knowledge, no 3D QSAR investigation of 
discodermolide analogs has been reported to date.25,27-30 
This proves the importance of QSAR studies involving this 
class of tubulin modulators.
As part of our ongoing research program aimed at 
designing new β-tubulin modulators, a rational structure-
based design strategy was employed to investigate the 
molecular recognition patterns required for specific 
β-tubulin binding, as schematically shown in Figure 2. In 
the present study, three-dimensional QSAR comparative 
molecular field analysis (3D QSAR CoMFA)31 models 
were developed for a series of synthetic discodermolide 
analogs using two different structural alignment methods 
in order to explore the high conformational flexibility of 
the compounds. In the CoMFA method, it is possible to 
represent the relationships between molecular properties 
(steric and electrostatic) and biological activity in the 3D 
protein environment of the β-tubulin binding site, indicating 
potential regions for obtaining specificity. The final 3D 
QSAR models along with the information gathered from 3D 
contour maps provided important insights into the structural 
and chemical basis for potent microtubule stabilization 
and antitumoral properties of this series of discodermolide 
derivatives. The identification of key intermolecular 
features associated with affinity and specificity should be 
a valuable tool for the design of promising candidates for 
clinical development.
Experimental
Data set
The data set used for the QSAR analyses contains 
42 discodermolide analogs.32-37 The structures and 
corresponding pIC50 values (−log IC50, where IC50 is the 
concentration of compound required for 50% inhibition 
of A549 lung carcinoma cell growth) for the whole set of 
ligands are presented in Table 1.
Computational approach
The QSAR modeling analyses, calculations, and 
visualizations for CoMFA were performed using the 
SYBYL 8.0 package (Tripos Inc., St. Louis, MO, USA) 
running on Red Hat Enterprise Linux workstations. The 
3D structures of the small molecule discodermolide 
modulators were constructed using standard geometric 
parameters of the SYBYL 8.0 package. Each single 
optimized conformation of each molecule in the data set 
was energetically minimized employing the Tripos force 
field and Gasteiger-Huckel charges.38,39 A hierarchical 
cluster analysis of the data set was carried out with Tsar 
3D (Accelrys, San Diego, CA).
Molecular alignment
Alignment is a crucial component in 3D QSAR studies, 
and a variety of useful approaches have been described in 
the literature.18-20 Two independent molecular alignment 
procedures were used in the present study: 
Figure 1. Natural products as microtubule-stabilizing antimitotic agents.
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(i) Rigid-body fit. The lowest energy conformer of 
discodermolide (compound 25, Table 1) was used as the 
template structure for the molecular alignment of the 
series of ligands. All molecules in their respective lowest 
energy conformations were individually superimposed 
on the template molecule by using an atom/centroid root 
mean square (RMS) fitting procedure, the rigid-body 
fit option in SYBYL 8.0. The alignment and maximal 
common substructure used for superposition are illustrated 
in Figure 3.
(ii) Receptor-based. Predicted binding modes of 
discodermolide and its analogs into the β-tubulin cavity 
have been previously proposed by using an integration 
of experimental evidences and computer-aided studies.25 
Docking and scoring protocols as implemented in GOLD 
3.1 (Cambridge Crystallographic Data Centre, Cambridge, 
UK) were used to investigate the possible binding 
conformations of the ligands within the discodermolide 
binding domain of β-tubulin.25,40 The X-ray crystallographic 
data for αβ-tubulin complexed with paclitaxel and 
epothilone (PDB IDs, 1JFF and 1TVK, respectively) used 
in the docking studies were retrieved from the Protein 
Data Bank (PDB).39,40 For the calculations, the ligands 
were removed and hydrogen atoms were added using 
the biopolymer module as implemented in SYBYL 8.0. 
The histidine, glutamine, and asparagine residues in the 
β-tubulin binding site were manually checked for possible 
flipped orientation, protonation, and tautomeric states with 
Pymol (DeLano Scientific, San Carlos, CA, USA). The 
binding site was centered on the O5 atom of the taxol and 
the O2 atom of epothilone and a radius sphere of 12 Å 
was considered for the docking procedures, which were 
repeated 10 times for each molecule due to the stochastic 
nature of the search algorithm. Default parameters and 
GOLDscore function were employed in all runs, and only 
the top-ranked conformations of each compound were 
considered for the CoMFA studies. The aligned data set is 
depicted in Figure 4.
Figure 2. Structure-based design strategy used to investigate the required molecular recognition patterns for specific β-tubulin binding and anticancer activity.
Figure 3. Three-dimensional data set alignment for minimized 
discodermolide analogs. (A) Rigid-body fit alignment. (B) Template molecule 
(discodermolide, maximal common substructure shown in gray).
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Structural and Chemical Basis for Anticancer Activity of a Series of β-Tubulin Ligands J. Braz. Chem. Soc.696
Table 1. Data set of discodermolide analogs employed in the 3D QSAR studies
Training set compounds
Comp. Structure pIC50 Comp. Structure pIC50 Comp. Structure pIC50
1 5.00 2 5.40 3 5.40
4 5.70 5 6.10 6 6.22
7 6.24 8 6.24 9 6.27
10 6.39 11 6.40 12 6.61
13 6.72 14 6.87 15 6.90
16 6.96 17 7.05 18 7.15
19 7.17 20 7.27 21 7.30
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Training set compounds
Comp. Structure pIC50 Comp. Structure pIC50 Comp. Structure pIC50
22 7.44 23 7.52 24 7.57
25 7.66 26 7.89 27 8.00
28 8.03 29 8.11 30 8.22
31 8.29 32 8.40 33 8.43
34 5.40 35 5.70 36 6.29
37 6.51 38 6.80 39 7.00
40 7.24 41 7.89 42 8.10
Table 1. Continuation
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3D QSAR studies
To better understand and explore the electrostatic and 
steric contributions to the binding of the discodermolide 
analogs, and to build predictive 3D QSAR models, 
CoMFA studies were performed based on the two 
molecular alignments described (Figures 3 and 4). Steric 
and electrostatic properties were calculated according to 
Lennard-Jones and Coulomb potentials, respectively. The 
aligned training set molecules were placed in a 3D grid box 
such that the entire set was included in it. CoMFA steric and 
electrostatic fields were generated at each grid point with the 
Tripos force field using a sp3 carbon atom probe carrying a +1 
net charge. The CoMFA grid spacing of 2.0 Å in the x, y, and 
z directions, and a grid region were automatically generated 
by the CoMFA routine to encompass all molecules with an 
extension of 4.0 Å in each direction.38 The CoMFA region 
focusing method was applied to increase the resolution of 
CoMFA models. The default value of 30 kcal mol−1 was set as 
the maximum steric and electrostatic energy cutoff. CoMFA 
descriptors were used as independent variables whereas pIC50 
values were used as dependent variables in the partial least 
squares (PLS) regression analyses to derive the 3D QSAR 
models. All models were investigated using full cross-
validated (q2) leave-one-out (LOO) and leave-many-out 
(LMO) methods, with CoMFA standard options for scaling 
of variables. The progressive scrambling method was applied 
to determine the sensitivity of the QSAR models to chance 
correlations. The models were externally validated with a 
test set of compounds, which were not considered for QSAR 
model generation. After generation of the PLS training set 
models, the dependent variables (pIC50) were predicted for 
the test set compounds, allowing predictive r2 values to be 
determined for individual 3D QSAR models.43,44
Results and Discussion
Chemical and biological data
3D QSAR CoMFA models were derived for a series 
of 42 discodermolide analogs for which IC50 values 
for the inhibition of A549 cell growth were collected 
(Table 1). The in vitro IC50 values employed in this work 
were measured under the same experimental conditions, 
a fundamental requirement for QSAR studies.32-37 The 
IC50 values vary from 3.7 to 10000 nM, a factor of about 
2700. The discodermolide analogs of the data set present 
structural variations at the C21-side chain, C19-carbamate 
group, C14-and C7-substituents, and in the lactone ring, as 
depicted in Figure 5. The values of IC50 were converted 
into the corresponding pIC50 values (Table 1), which span 
approximately three and a half orders of magnitude, and 
are acceptably distributed across the range of pIC50 values 
(Figure 6).
The generation of consistent statistical models depends 
on the quality of both training and test sets in terms of 
Figure 4. Three-dimensional data set alignment for conformations 
generated by GOLD 3.1.
Figure 5. Structural variations presented by the 42 discodermolide 
analogs of the data set.
Figure 6. Distribution of pIC50 values for the training set, test set and 
complete data set.
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structural diversity and property value distributions. 
From the original data set, 33 compounds (1-33, Table 1) 
were selected as members of the training set for model 
generation, whereas the other 9 compounds (34-42, Table 1) 
were selected as members of the test set for external model 
validation. The compounds of the training and test sets were 
carefully selected in order to ensure appropriate property 
coverage on the entire range of pIC50 values (Figure 6). A 
statistical cluster analysis confirmed that the composition 
of both training and test sets is representative of the whole 
data set, as can be seen in Figure 6. Thus, the data set is 
appropriate for the purpose of QSAR model development. 
The same training set was employed for all 3D QSAR 
analyses, and the predictive ability of the models was 
assessed by their q2 values and external test set predictions 
(predictive r2 values).
Molecular alignment strategies
The determination of the spatial structural alignments of 
the discodermolide analogs in the binding pocket of β-tubulin 
can critically affect the outcome of the CoMFA studies, 
since the analyses are highly dependent on the quality of 
the alignments. 3D structural information on the interaction 
of small molecule modulators with the β-tubulin cavity is 
limited to crystal structures of the complexes of αβ-tubulin 
dimers with paclitaxel, docetaxel and epothilone A (PBD IDs 
JFF, 1TUB and 1TVK, respectively).41,42 Although tubulin-
discodermolide complexes are not available to date, the 
crystal structures of the known receptor-ligand complexes 
have provided an important basis for the understanding of 
the fundamental chemical and structural requirements for 
β-tubulin binding by the discodermolide analogs. However, 
it should be noted that the scenario is more complex due to 
the high flexibility of the discodermolide system, creating 
new challenges in the drug design arena. For this reason, 
two molecular alignment approaches were used in the 
present study. In the first case we have applied a receptor-
independent strategy derived from a rigid superimposition of 
the minimum energy conformations of the discodermolide 
analogs (Figure 3), while in the second case we have 
employed a receptor-based approach (Figure 4).
Taxanes and epothilones have been found to overlap 
in their occupation of a rather expansive common binding 
cavity of β-tubulin, exploiting the binding pocket in a 
unique and different manner. Considering the experimental 
evidence that indicates that the β-tubulin cavity can 
accommodate discodermolide and its synthetic analogs, as 
well as a variety of structurally diverse tubulin modulators, 
the crystal structures of β-tubulin complexed with paclitaxel 
(PDB ID 1JFF) and epothilone A (PDB ID 1TVK) were 
used in the receptor-based molecular docking studies, 
in such a way to explore the significant conformational 
flexibility of both receptor cavity and ligands.41,42 The two 
structures were superposed on one another using the Cα 
atoms to characterize the binding cavity and to identify the 
most important variable regions. In particular, tautomeric, 
rotameric, protonation states and different 3D positions of 
Asp26, Leu215, Asp224, His227, Leu228, Thr274, Arg276, 
Arg282, Arg359 and Gly360 were carefully examined. 
Following the completion of the molecular alignment 
processes, the discodermolide conformations generated 
were individually inspected and no conformational 
problem was identified. When considering all possible 
intermolecular interactions of the compounds, the receptor-
based flexible alignment represented the best overall 
structural alignment strategy, while the rigid-body fit 
alignment was characterized for a specific superposition 
region around a pre-defined common substructure, as can be 
observed in Figures 3 and 4. Importantly, the 3D molecular 
differences in the two distinct alignment approaches were 
quantitatively investigated using the CoMFA method, 
through its steric and electrostatic fields.
3D QSAR models
The CoMFA method is based on the assumption that 
changes in ligand-binding affinities are related to changes 
in molecular properties represented by 3D molecular fields. 
Therefore, in order to investigate the structural and chemical 
features related to the biological activity of this series of 
discodermolide analogs, the two molecular alignments 
developed in this work were analyzed using the CoMFA 
steric and electrostatic fields.31,45 The structural alignments 
depicted in Figures 3 and 4 were employed in several PLS 
analyses, and the models were optimized through the 
CoMFA region focusing method. The region focusing was 
weighted by StDev*Coefficient values ranging from 0.3 to 
1.5 and grid spacing ranging from 0.5 to 2.0. This strategy 
not only increased q2 values during the process of model 
generation, but also resulted in the refinement of 3D contour 
maps. The best statistical results are presented in Table 2. 
As can be seen, significant correlation coefficients were 
obtained, with a cross-validated correlation coefficient q2 
of 0.68 and a conventional non-cross-validated correlation 
coefficient r2 of 0.94 for the rigid-body fit alignment, 
while a q2 of 0.63 and an r2 of 0.91 for the receptor-based 
alignment. LMO procedures were performed in both cases 
as a more rigorous test for the stability and statistical 
significance of the models. Accordingly, the data set was 
divided into 10 (LMO10) and 5 (LMO5) randomly selected 
groups and, subsequently, each group was left out during 
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the cross-validation process. Each model was evaluated 25 
times by measuring its accuracy in predicting the activity 
of the remaining 10% and 20% data set compounds. The 
results confirmed the stability and reliability of the 3D 
QSAR models, considering that the statistical values 
obtained for the LMO analyses were comparable to those 
of the LOO analyses. Progressive scrambling of the data 
set was also carried out to determine the sensitivity of 
the QSAR models to chance correlations and to test the 
stability of the models. The results further confirmed the 
consistency of the models as defined by the critical slope, 
and optimum statistics for cSDEP and Q**2 obtained at 
the end of different runs. In sum, the models generated in 
this study are very stable and possess substantial statistical 
significance and high internal predictive ability.
Although the q2LOO and q2LMO procedures may give a 
suitable representation of the predictive power of the models 
for untested tubulin modulators, the external validation 
process can be considered the most valuable validation 
method.19-25,43,44 Therefore, the predictive ability of the 
internally consistent CoMFA models generated employing 
the 33 training set molecules (compounds 1-33, Table 1) was 
assessed using an external test set containing 9 compounds 
(compounds 33-42, Table 1), which were completely 
excluded from model generation. Prior to prediction, the test 
set compounds were processed identically to the training set 
compounds. On the basis of the appropriate representation 
of chemical diversity and distribution of property values 
(Table 1 and Figure 6), the test set meets the requirements 
for the purpose of external model validation. The detailed 
list of experimental and predicted pIC50 values are shown in 
Table 3 and the graphic results simultaneously displayed in 
Figure 7. Predictive r2
 
values of 0.68 and 0.85 were obtained, 
respectively, for the rigid-body fit and receptor-based models 
(Table 2). Hence, in addition to good statistical quality 
and internal consistency, the models show high predictive 
power for novel β-tubulin modulators within this structural 
diversity. The good agreement between experimental and 
predicted pIC50 values also indicates the robustness of the 
predictive QSAR models.
As can be seen, the receptor-based CoMFA model 
possesses higher predictive ability than the corresponding 
rigid-body fit model, as indicated by its predictive r2 
value and lower residual values (Table 3). In addition, the 
relative contributions of the steric and electrostatic fields 
Table 3. Experimental and predicted activities (pIC50) with residual 
values for the test set compounds. Rigid-body fit (i) and receptor-based 
(ii) structural alignments
Comp. Experimentala Predicted CoMFA(i)a
CoMFA(i) 
residualsb
Predicted 
CoMFA(ii)a
CoMFA(ii) 
residualsb
34 5.40 5.93 −0.53 5.90 −0.50
35 6.29 6.86 −0.57 6.17 0.12
36 7.00 6.73 0.27 7.01 −0.01
37 7.89 6.80 1.09 7.19 0.70
38 5.70 6.02 −0.32 5.83 −0.13
39 8.10 7.69 0.41 7.94 0.16
40 6.51 6.52 −0.01 5.97 0.54
41 7.24 7.44 −0.20 7.22 0.02
42 6.80 7.14 −0.34 6.76 0.04
apIC50 values. bThe difference between experimental and predicted 
values.Table 2. COMFA results
Alignment q2 N r2 SEE r2pred
Fraction
S E
Rigid-body fit 0.68 6 0.94 0.23 0.68 0.30 0.70
Receptor-based 0.63 6 0.91 0.31 0.85 0.53 0.47
q2, Leave-one-out (LOO) cross-validated correlation coefficient; 
N, optimum number of components; r2, non-cross-validated correlation 
coefficient; SEE, standard error of estimate; r2pred, external prediction 
coefficient; S, steric field; E, electrostatic field. 
Figure 7. Plot of predicted values of pIC50 versus the corresponding 
experimental values for the training (black squares) and test (gray squares) 
compounds for rigid-body fit (A) and receptor-based (B) structural 
alignments.
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to the biological activity are different for the two models. 
According to the data of Table 2, the CoMFA steric field 
descriptor for the rigid-body fit model explained 30% of 
the variance, while the electrostatic descriptor accounted 
for the remaining 70%. For the receptor-based model, the 
corresponding steric and electrostatic fields explained 53% 
and 47%, respectively. The results of the receptor-based 
CoMFA model are in accordance with previous classical 
and 3D QSAR studies on the interaction of taxanes in 
the tubulin/microtubule system, which indicated that the 
hydrophobic feature of the substituents along with the 
steric parameters/fields are the most important determinants 
of biological activity and directly reflect the chemical 
environment of the tubulin binding pocket.27,28
In addition to prediction of property values for the test 
set molecules, the derived 3D QSAR CoMFA models should 
also provide insights into molecular properties intrinsically 
related to receptor-binding affinity and biological activity. 
One prominent feature of the CoMFA method is the easy 
visualization of the steric and electrostatic regions in space 
responsible for increases and decreases in the values of a 
particular type of dependent variable (e.g., pIC50). The 3D 
contour maps generated in our studies represent an important 
tool for the understanding of specific tubulin-discodermolide 
interactions related to the antimitotic activity.
The specialized molecular fields can be analyzed 
considering two aspects in the CoMFA contour maps. 
Unfavorable steric regions are represented in yellow 
and favorable steric regions in green, while red contours 
represent regions where electronegative substituents may 
increase the biological activity, and blue contours indicate 
regions where electropositive groups would contribute to 
enhance the antimitotic potency. For comparison purposes, 
the CoMFA electrostatic contour maps for the rigid-body 
fit and receptor-based models are shown in Figure 8 as 
PLS StDev*Coefficient plots, using the discodermolide 
analog 32 (Table 1). Although the importance of the 
C19-carbamate and lactone carbonyl groups, as well as the 
electronegative substituents near C17 is emphasized in both 
alignment models, only the receptor-based model present 
a red contour surrounding the (S)-C7 region, indicating 
that electronegative groups (hydrogen bond acceptors) 
are related to increasing antimitotic potency. These 
observations are in agreement with prior experimental 
evidence that suggests the importance of the substituents 
at C19-carbamate, (R)-C17-hydroxyl, and (S)-C7-hydroxyl, 
and the carbonyl oxygen of the lactone ring to the observed 
discodermolide cytotoxicity.25,37,46,47
The corresponding steric fields for the two generated 
molecular alignments are depicted in Figure 9. The green 
contours surrounding the lactone ring of the discodermolide 
analog (compound 32, Table 1) suggest that bulky 
substituents would be favorable in that region according to 
both rigid-body fit and receptor-based steric contour maps. 
However, the receptor-based contour map explained this 
steric region in more detail, revealing that bulkier groups 
surrounding the lactone ring region would be detrimental 
for antimitotic potency, as emphasized by the unfavorable 
steric regions depicted in the yellow maps. Furthermore, 
the C14-substituent was found to be important to increasing 
cytotoxicity, and this result is also in accordance with 
previous studies.25,48
The 3D receptor-based model generated in this study is 
compatible with the chemical environment of the β-tubulin 
binding cavity, as shown in Figure 10. The importance of 
the C19-carbamate, (R)-C17-hydroxyl, C14-methyl and (S)-
C7-hydroxyl substituents, and the lactone ring corroborates 
with the β-tubulin interaction sites Asp26, Gly360, Phe270, 
Arg276 and His227, as previously reported.25,37,46-48 As can 
be seen in the docking position obtained for discodermolide 
(Figure 10), the lactone ring fits in the Asp224/His227 pocket 
and leads to the formation of a hydrogen bond between the 
Figure 8. CoMFA electrostatic contour maps (as SD × coefficient). 
(A) Rigid-body fit alignment. (B) Receptor-based alignment. Higher 
values of pIC50 are correlated to more positive charge near blue and more 
negative charge near red. Compound 32 is displayed in the background 
for reference.
Figure 9. CoMFA steric contour maps (as SD × coefficient). (A) Rigid-
body fit alignment. (B) Receptor-based alignment. Higher values of pIC50 
are correlated to more bulky groups near green and less bulky groups near 
yellow. Compound 32 is displayed in the background for reference.
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Figure 10. Three-dimensional model of discodermolide (compound 25) in the 
β-tubulin binding cavity along with CoMFA steric and electrostatic fields.
carbonyl oxygen and the side chain of Arg276, while the 
C19-carbamate NH2 group is oriented toward the side chain 
of Asp26 to form an additional hydrogen bond. The (S)-C7-
hydroxyl substituent is also hydrogen-bonded to Arg276 
and the C14-methyl group interacts with Phe270 through 
hydrophobic contacts. The identification of these important 
structural features should be useful for the design of new 
structurally related MSAAs with improved potency.
Conclusions
The understanding of protein-ligand intermolecular 
interactions is essential for the design of compounds 
with improved affinity and biological potency.17,22 This 
assumption is particularly evident in the case of the highly 
flexible discodermolide modulators analyzed in this 
study. Robust 3D QSAR CoMFA models were developed 
employing two distinct alignment strategies, and the 
models possess high internal and external consistency, 
showing substantial predictive power. The CoMFA contour 
maps emphasized important regions in 3D space where 
modifications of steric and electrostatic fields would 
be strongly associated with concomitant changes in the 
observed antimitotic potency. In addition, the receptor-
based model generated was compatible with the 3D protein 
environment in the β-tubulin binding site and, therefore, 
could be used to guide further structural modifications as 
well as structure-based design of new β-tubulin modulators 
with improved affinity and potency. The integration of 
molecular modeling and 3D QSAR studies was a useful 
tool for the identification of chemical and structural features 
responsible for binding affinity, microtubule stabilization 
and antitumoral properties of this series of discodermolide 
derivatives.
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